Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes

Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes

Variation in the preservation of β cell function in clinical trials in type 1 diabetes (T1D) has emphasized the need to define biomarkers to predict treatment response. The T1DAL trial targeted T cells with alefacept (LFA-3–Ig) and demonstrated C-peptide preservation in approximately 30% of new-onse...

Full description

Bibliographic Details
Main Authors: Elisa Balmas, Janice Chen, Alex K. Hu, Hannah A. DeBerg, Mario G. Rosasco, Vivian H. Gersuk, Elisavet Serti, Cate Speake, Carla J. Greenbaum, Gerald T. Nepom, Peter S. Linsley, Karen Cerosaletti
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-11-01
Series:JCI Insight
Subjects:
Autoimmunity
Online Access:https://doi.org/10.1172/jci.insight.167881

Internet

https://doi.org/10.1172/jci.insight.167881

Similar Items